There is no active application for the product registration of zuranolone—the first and only oral treatment for postpartum depression (PPD)—in the Philippines, the Food and Drug Administration (FDA) said on Tuesday, Aug. 8. Courtesy of MB (File photo) "Currently, there is no ongoing application...